News
NKTX
2.250
+1.35%
0.030
Weekly Report: what happened at NKTX last week (1005-1009)?
Weekly Report · 3h ago
Nkarta: NKX019 Autoimmune Safety and Early Efficacy Support Reiterated Buy Rating and Unchanged $11 Price Target
TipRanks · 10/05 11:25
Weekly Report: what happened at NKTX last week (0928-1002)?
Weekly Report · 10/05 10:18
Nkarta (NKTX) Receives a Buy from Stifel Nicolaus
TipRanks · 09/28 10:56
Weekly Report: what happened at NKTX last week (0921-0925)?
Weekly Report · 09/28 10:14
H.C. Wainwright Reaffirms Their Buy Rating on Nkarta (NKTX)
TipRanks · 09/22 09:45
Weekly Report: what happened at NKTX last week (0914-0918)?
Weekly Report · 09/21 10:14
Weekly Report: what happened at NKTX last week (0907-0911)?
Weekly Report · 09/14 10:19
Nkarta Insiders Got A Good Deal Selling At US$2.10
Simply Wall St · 09/09 10:11
Weekly Report: what happened at NKTX last week (0831-0904)?
Weekly Report · 09/07 10:12
Nkarta: 'Hold' NKX019 Discontinuation For R/R NHL And Pivot To Autoimmune Disorders
Seeking Alpha · 09/03 14:22
Weekly Report: what happened at NKTX last week (0824-0828)?
Weekly Report · 08/31 10:19
Weekly Report: what happened at NKTX last week (0817-0821)?
Weekly Report · 08/24 10:20
Mizuho Securities Sticks to Their Buy Rating for Nkarta (NKTX)
TipRanks · 08/17 16:15
Weekly Report: what happened at NKTX last week (0810-0814)?
Weekly Report · 08/17 10:21
Nkarta price target lowered to $10 from $11 at Stifel
TipRanks · 08/16 13:43
Nkarta Is Maintained at Buy by Stifel
Dow Jones · 08/14 12:34
Analysts Are Bullish on Top Healthcare Stocks: Idexx Laboratories (IDXX), Nkarta (NKTX)
TipRanks · 08/14 11:40
Nkarta Price Target Cut to $14.00/Share From $16.00 by HC Wainwright & Co.
Dow Jones · 08/11 12:45
Nkarta Is Maintained at Buy by HC Wainwright & Co.
Dow Jones · 08/11 12:45
More
Webull provides a variety of real-time NKTX stock news. You can receive the latest news about Nkarta, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About NKTX
Nkarta, Inc. is a clinical-stage biopharmaceutical company advancing the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is developing NKX019, a chimeric antigen receptor-natural killer (CAR NK) product candidate targeting the CD19 antigen for the treatment of patients with autoimmune diseases and NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands. NKX019 is engineered with a humanized CD19-directed CAR for enhanced cell targeting and a proprietary, membrane-bound form of interleukin-15 (IL-15) for greater persistence and activity without exogenous cytokine support. CD19 is a biomarker for normal B cells as well as those implicated in autoimmune disease and B cell-derived malignancies. Its NKX019 autoimmune program is based on the potential to eliminate the pathologic B cells that produce autoantibodies.